In a findings release that challenges the bedrock of modern preventative cardiology, researchers at the Mount Sinai Health System have issued a stark warning: the most common tools used to predict heart attacks are missing the mark for nearly half of the patients who experience them. The study, published on November 21 in the Journal of the American College of Cardiology: Advances, suggests that the reliance on population-based risk calculators and symptom-reporting may be providing a false sense of security to millions of individuals, effectively delaying life-saving interventions until it is too late.
Main Facts: A Systemic Failure in Prediction
For decades, the standard of care for cardiovascular prevention has relied on the Atherosclerotic Cardiovascular Disease (ASCVD) risk score. This mathematical model, typically applied to adults between the ages of 40 and 75, calculates the 10-year likelihood of a heart attack or stroke based on a composite of age, biological sex, race, blood pressure, cholesterol levels, diabetic status, and smoking history.
In recent years, a newer, more comprehensive tool known as the PREVENT calculator was introduced to provide a more nuanced picture of cardiovascular risk. However, the Mount Sinai study—a retrospective analysis of 474 patients who suffered their first heart attack—revealed that these tools are fundamentally limited. When researchers simulated the clinical evaluation of these patients just 48 hours before their cardiac events, they discovered that current guidelines would have left a significant portion of them untreated.
Specifically, 45% of the patients studied would not have qualified for preventive therapy or further diagnostic testing under the standard ASCVD guidelines. When the more modern PREVENT tool was applied, that number ballooned to 61%. These findings suggest that the “gatekeeper” model of cardiovascular medicine—which uses risk scores to determine who receives treatment and who is told they are at low risk—is in dire need of an overhaul.
Chronology: Tracing the Path to an Event
To understand the efficacy of these tools, the research team conducted an exhaustive retrospective review of patients treated at The Mount Sinai Hospital and Mount Sinai Morningside between January 2020 and July 2025. All 474 participants were under the age of 66 and had no previously diagnosed coronary artery disease, making them prime candidates for standard "low to intermediate risk" classifications.
The Simulated Evaluation
The researchers reconstructed the clinical picture for each patient as it would have appeared two days before their heart attack. By inputting the patients’ demographic information, medical history, and clinical markers (cholesterol and blood pressure) into both the ASCVD and PREVENT calculators, the team categorized each patient into four risk tiers:
- Low: Under 5% 10-year risk
- Borderline: 5% to 7.5% 10-year risk
- Intermediate: 7.5% to 20% 10-year risk
- High: Above 20% 10-year risk
The results were sobering. A vast majority of the patients who suffered a catastrophic cardiac event would have been funneled into the "low" or "borderline" categories. In clinical practice, these patients are almost universally reassured, provided with general lifestyle advice, and sent home without the initiation of statins or the pursuit of diagnostic imaging.
The study further highlighted the danger of relying on symptomatic presentation. The data showed that 60% of the patients experienced their first symptoms—such as chest pain or shortness of breath—less than 48 hours before their heart attack occurred. This indicates that symptoms are not an early warning system, but rather a late-stage signal of a disease process that has already advanced to the point of imminent failure.
Supporting Data: Why Population Tools Fail the Individual
The core issue identified by the Mount Sinai team is the discrepancy between population-based statistics and individual biological reality. Risk scores are designed to function well when looking at large cohorts of people; they are excellent at identifying trends across millions of lives. However, they are often blunt instruments when applied to the specific anatomy of one person.
"Our research shows that population-based risk tools often fail to reflect the true risk for many individual patients," explains Dr. Amir Ahmadi, the study’s corresponding author and a Clinical Associate Professor of Medicine (Cardiology) at the Icahn School of Medicine at Mount Sinai.
The data underscores a "prevention gap." Because the current medical model mandates that physicians only escalate care for those who hit a specific numerical threshold on a risk calculator, those who fall below that threshold remain in a "blind spot." This creates a paradox where a patient who has significant, silent atherosclerosis—buildup of plaque in the arteries—is categorized as "low risk" simply because their blood pressure or cholesterol numbers are not sufficiently elevated, or because they haven’t yet reported chest pain.
Official Responses and Clinical Perspectives
The implications of this study have sent ripples through the cardiology community, prompting a discussion on the necessity of moving toward more direct diagnostic approaches. Dr. Anna Mueller, an internal medicine resident at the Icahn School of Medicine and the study’s first author, emphasizes that the reliance on these scores can lead to a dangerous complacency.
"Most heart attacks occur in patients in the low or intermediate risk groups," Dr. Mueller notes. "This study highlights that a lower risk score, along with not having classic heart attack symptoms—which is common—is no guarantee of safety on an individual level."
Dr. Ahmadi and his colleagues are advocating for a fundamental shift in how doctors identify at-risk patients. Rather than relying on the "gatekeeper" of risk calculators, the team suggests that the medical community should prioritize early atherosclerosis imaging. By identifying the presence of silent plaque before it ruptures, clinicians could theoretically intervene with protective therapies years before a patient reaches the point of an acute event.
This perspective is gaining traction among experts who argue that we have the technology to see the disease, but we lack the guidelines to mandate its use. While current guidelines favor risk calculators due to their low cost and ease of use in primary care, the Mount Sinai study serves as a potent reminder that cost-efficiency should not come at the expense of clinical accuracy.
Implications: A New Era for Preventative Cardiology
The Mount Sinai findings serve as a clarion call for the future of heart health. The implications for the medical field are threefold:
1. The Shift to Imaging
If risk scores are failing to identify the patients who actually go on to have heart attacks, the logical next step is to look for the disease itself. Cardiovascular imaging—such as coronary artery calcium (CAC) scoring or CT angiography—can visualize the extent of plaque buildup. Integrating these tools into routine physicals for individuals who might otherwise be dismissed as "low risk" could revolutionize early detection.
2. Redefining "Low Risk"
The medical establishment may need to reconsider what it means to be "low risk." The study suggests that for many, the label is inaccurate. A patient with no symptoms and a "good" risk score may still be harboring unstable plaque that is ready to rupture. This necessitates a more personalized approach to medicine that takes into account family history, subclinical markers, and direct visualization of the coronary arteries.
3. Early Intervention
The study reinforces the importance of acting before the onset of symptoms. Because 60% of the patients in the study only experienced symptoms two days prior to their heart attack, the window for effective intervention based on symptoms is effectively nonexistent. By shifting the focus to detecting "silent" atherosclerosis, physicians can manage cholesterol, blood pressure, and inflammation long before the plaque becomes dangerous.
Conclusion: Moving Forward
While the study provides a critical critique of current practices, the authors acknowledge that this is only the beginning of a larger conversation. More research is required to determine the most effective, scalable ways to implement early imaging and to refine the next generation of risk assessment tools.
For now, the Mount Sinai research serves as a reminder to both patients and providers: a "low" risk score is not a clean bill of health, and the absence of symptoms is not an absence of disease. As the medical community digests these findings, the hope is that cardiology will move away from the safety of population-wide averages and toward the precision of individualized, evidence-based care. The path to saving more lives, the researchers suggest, lies in the ability to see the silent threat before it becomes a tragedy.
